US govt faces calls to green-light prostate cancer drug generics

Annual global sales of Pfizer and Astella blockbuster drug reach roughly $5 billion | Nonprofits argue the drug is sold at a price three to six times higher in the US than it’s priced in other similar high-income countries | Move to curb drug prices follows controversial march-in rights plan.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Pharma

Lilly loses Fed Circ rehearing bid, sparking enablement questions

1 October 2026 The decision leaves a $177 million verdict against Lilly intact, but a dissenting judge has warned the ruling could “undermine medical innovation” by allowing overly broad patent claims to survive and provide a way around the Supreme Court’s Amgen decision.

Pharma

Takeda sees off UK challenge to Elvanse SPC

28 September 2026 Can a drug’s ‘inactive’ precursor qualify for a multi-million pound patent extension? The UK High Court has just delivered a ruling on Takeda's ADHD drug Elvanse, weighing regulatory precedent against a conflicting German decision.

Pharma

Mylan throws down new gauntlet in Novo Wegovy patent fight

25 September 2026 Another Wegovy patent has been drawn into the long-running dispute between Mylan and Novo Nordisk over proposed generic versions of the weight-loss drug.

More features

What's AI best at? In-house teams are still learning

WATCH: Genevant IP director on tackling UPC-EPO opposition divide

5 LSPN takeaways: What’s keeping Europe’s IP teams on their toes?

Lilly loses Fed Circ rehearing bid, sparking enablement questions

Westlaw publisher scores landmark AI copyright win in US appeals court

Scientist and Chinese biotech targeted by Beam in secrets suit

Clifford Chance recruits new head of Asia-Pac

Takeda sees off UK challenge to Elvanse SPC

US govt faces calls to green-light prostate cancer drug generics

More on this story

Editor's picks

Editor's picks

More features